Compare Johnson & Johnson (JNJ) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs MINISO Group Holding Ltd — how do they compare? Johnson & Johnson trades at $259.32 (market cap $618.09B), while MINISO Group Holding Ltd trades at $9.58 (market cap $2.65B). The key difference: Johnson & Johnson is far larger — about 233.2× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (7.34%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and MINISO Group Holding Ltd for 24 Days on average.
| JNJ | MNSO | |
|---|---|---|
Market Cap | $618.09B | $2.65B |
Volume | 6,050,983 | 747,763 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $22.75 |
52-Week Low | $186.00 | $8.60 |
Typical Hold Time | 129 Days | 24 Days |
Enterprise Value | $646.37B | $3.52B |
Dividend Yield | 2.09% | 7.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages and a mixed earnings history. The company reported 2025 revenue of $21.44 billion and net income of $1.21 billion, with a P/E of 14.76 and P/S of 0.79 indicating reasonable valuation. Recent news highlights CFO share purchases and earnings volatility, with analyst consensus leaning bullish at 60% buy ratings.
The outlook for MNSO balances growth potential from domestic expansion against earnings inconsistency and competitive pressures. Investment appeal lies in its value metrics and operational scale, but risks include margin compression and market sentiment shifts. The stock's near-term direction hinges on sustained profitability improvements and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
